Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.hillstreambio.com
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and proprietary novel bovine-derived biologic platform, PicoKnobTM, targeting undruggable epitopes on PD-1 and TROP2 Experienced biopharmaceutical executive joins as Chief Operating Officer to spearhead execution of ADC and biologic strategy BRIDGEWATER, N.J., July 10, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma (NASDAQ:HILS) a biotechnology company developing innovative therapeutic candidates targeting drug resistant and devastating cancers that can make a difference in patients' lives,
BRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the appointment of Kelly Anderson to its Board of Directors and committees, effective as of May 9, 2023. Mrs. Anderson brings over 25 years of experience in public company finance, accounting and corporate governance across a variety of industries and will be instrumental in guiding Hillstream with its or
SC 13G/A - Tharimmune, Inc. (0001861657) (Subject)
SC 13G - Tharimmune, Inc. (0001861657) (Subject)
Expects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases announced a corporate name change to Tharimmune, Inc., ("Tharimmune"). The corporate name change is based on the Greek word "thárros", translated to mean courage and reflects the transformation of the Company into a patient-focused, clinical development organization. The Company's common stock will trade on The Nasdaq Capital Market under a new t
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancer announces an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved IND. AV104 has a dual mechanism of action by affecting multiple rec
Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held in person and virtually from September 11-13, 2023. Event: H.C. Wainwright Presentation On-DemandDate: September 11th, 2023Time: 7:00am ETRegistration: Link *Please note that Company presentation
Management will present and hold virtual 1-on-1 meetings with institutional investors and analystsCompany recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and Minotaur Therapeutics, Inc. BRIDGEWATER, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics
Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on HER2/HER3 receptors Capitalizes on "Knob" biologics (PicobodiesTM) for tumor targeting, extends partnership to include validated target, HER3 IND filing for HSB-3215 planned in 2024 BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. ("Hillstream", the "Company") today announced the expansion of its collaboration with Minotaur Therapeutics, Inc. ("Minotaur") and its license agreement with OmniAb, Inc. ("OmniAb") to advance the development of next generation targeted Knob biologics (PicobodiesTM) against H
Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and proprietary novel bovine-derived biologic platform, PicoKnobTM, targeting undruggable epitopes on PD-1 and TROP2 Experienced biopharmaceutical executive joins as Chief Operating Officer to spearhead execution of ADC and biologic strategy BRIDGEWATER, N.J., July 10, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma (NASDAQ:HILS) a biotechnology company developing innovative therapeutic candidates targeting drug resistant and devastating cancers that can make a difference in patients' lives,
Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors Antibody CDRs against HER2 and HER3 Conformational Domain Bridging Epitopes can be used in multiple formats including bi- and tri-specific antibodies, antibody drug conjugates (ADCs), CAR-T and CAR-NKs BRIDGEWATER, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using immuno-oncology targeted novel biologics, today announced th
BRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the appointment of Kelly Anderson to its Board of Directors and committees, effective as of May 9, 2023. Mrs. Anderson brings over 25 years of experience in public company finance, accounting and corporate governance across a variety of industries and will be instrumental in guiding Hillstream with its or
NEW YORK, NY / ACCESSWIRE / May 9, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject to change, please visit www.sidoti.com/events for the most updated version and webinar links. For investor registration and to request 1x1 meetings, please visit https://www.sidoti.com/events/may-micro-cap-virtual-conference.Presentation Schedule *All Times EDTWednesday, May 10th, 2023 (Day 1)8:30-9:00Coda Octopus Group, Inc. (CODA)*****Hillstream BioPharma, Inc. (HILS)SosTravel.com SpA (SOSAF)9:15-9:45ReWalk Robotics (RWLK)GigaCloud Technology Inc (GC
BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the closing of its previously announced public offering of common stock. Hillstream sold 5,300,000 shares of its common stock at a public offering price of $0.50 per share for gross proceeds of $2,650,000 before deducting underwriting discounts and offering expenses. In addition, the Company has granted t
8-K - Tharimmune, Inc. (0001861657) (Filer)
8-K - Tharimmune, Inc. (0001861657) (Filer)
8-K/A - Tharimmune, Inc. (0001861657) (Filer)
8-K - Tharimmune, Inc. (0001861657) (Filer)
8-K - Tharimmune, Inc. (0001861657) (Filer)
424B5 - Tharimmune, Inc. (0001861657) (Filer)
EFFECT - Tharimmune, Inc. (0001861657) (Filer)
8-K - Tharimmune, Inc. (0001861657) (Filer)
FWP - Tharimmune, Inc. (0001861657) (Subject)
S-1/A - Tharimmune, Inc. (0001861657) (Filer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
4 - Tharimmune, Inc. (0001861657) (Issuer)
3 - Hillstream BioPharma Inc. (0001861657) (Issuer)
4/A - Hillstream BioPharma Inc. (0001861657) (Issuer)
4 - Hillstream BioPharma Inc. (0001861657) (Issuer)
4 - Hillstream BioPharma Inc. (0001861657) (Issuer)
Expects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares rose 38.4% to $0.14 during Friday's pre-market session. The company's market cap stands at $2.8 million. Synaptogenix (NASDAQ:SNPX) stock rose 13.69% to $0.32. The market value of their outstanding shares is at $3.2 million. Hillstream BioPharma (NASDAQ:HILS) stock increased by 13.68% to $0.26. The market value of their outstanding shares is at $4.4 million. SeaStar Medical Holding (NASDAQ:ICU) shares moved upwards by 12.9% to $0.21. The company's market cap stands at $4.0 million. Alpha Teknova (NASDAQ:TKNO) shares increased by 12.23% to $2.11. The market value of their outstanding shares is at $85.9 million. Agile Therapeutics (NASDAQ:A
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 63.8% to $26.16 during Monday's regular session. As of 13:30 EST, Crinetics Pharmaceuticals's stock is trading at a volume of 21.3 million, which is 4355.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.4 billion. Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 42.8% to $0.38. As of 13:30 EST, this security is trading at a volume of 98.4 million shares, making up 278.6% of its average full-day volume over the last 100 days. The company's market cap stands at $60.2 million. Akanda (NASDAQ:AKAN) stock rose 30.3% to $0.86. Trading volume for Akanda's st
Gainers iCoreConnect Inc. (OTC:ICCT) rose 88% to $23.09 in pre-market trading after jumping 119% on Wednesday. Last Friday, the company announced theclosing of its previously announced business combination with FG Merger Corp., a special purpose acquisition corporation (SPAC). noco-noco Inc. (NASDAQ:NCNC) shares gained 55% to $2.47 in pre-market trading after falling 20% on Wednesday. Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares climbed 37% to $2.22 in pre-market trading after the company announced the publication of its clinical validation of a novel drug-specific DRP®-companion diagnostic for dovitinib in the peer-reviewed journal PLOS ONE. Infobird Co., Ltd (NASDAQ:IFBD) share
On Tuesday, 210 companies reached new 52-week lows. Interesting Points From Today's 52-Week Lows: Enbridge (NYSE:ENB) was the largest firm by market cap to set a new 52-week low. First Wave BioPharma (NASDAQ:FWBI) was the smallest company in terms of market cap to set a new 52-week low. Republic First Bancorp (NASDAQ:FRBK)'s stock came under the most pressure, trading down 37.14% to reach a new 52-week low. Monro (NASDAQ:MNRO)'s stock bounced back the most, actually rising 0.0% after reaching its new 52-week low. The stocks that set new 52-week lows on Tuesday: Enbridge (NYSE:ENB) stock set a new 52-week low of $34.46 on Tuesday, moving down 0.63%. Target (NYSE:TGT) stock hit
Gainers Zynerba Pharmaceuticals (NASDAQ:ZYNE) shares moved upwards by 283.5% to $1.3 during Monday's regular session. Trading volume for this security as of 13:30 EST is 20.3 million, which is 10431.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $69.7 million. Taysha Gene Therapies (NASDAQ:TSHA) shares rose 120.41% to $1.63. Trading volume for this security as of 13:30 EST is 115.9 million, which is 46986.9% of its average full-day volume over the last 100 days. The company's market cap stands at $104.5 million. As per the news, the Q2 earnings report came out today. Virios Therapeutics (NASDAQ:VIRI) stock rose 26.57% to $1.09.
Gainers BioNexus Gene Lab Corp (NASDAQ:BGLC) shares surged 50.1% to $7.31 in pre-market trading. BioNexus Gene Lab reported pricing of $5 million public offering and uplisting to the Nasdaq Capital Market. Greenbrook TMS Inc. (NASDAQ:GBNH) shares gained 21.2% to $0.40 in pre-market trading. Greenbrook TMS recently entered into equity purchase agreement with Alumni Capital LP. Digital World Acquisition Corp. (NASDAQ:DWAC) gained 21% to $16.17 in pre-market trading. Digital World reached settlement with the SEC, paving way for Form S-4 registration statement review. Emergent BioSolutions Inc. (NYSE:EBS) shares gained 16.2% to $8.20 in pre-market trading after the FDA approved the compa
Upgrades Canaccord Genuity upgraded the previous rating for Lilium NV (NASDAQ:LILM) from Hold to Buy. NoneThe current stock performance of Lilium shows a 52-week-high of $3.25 and a 52-week-low of $0.37. Moreover, at the end of the last trading period, the closing price was at $1.32. Alliance Global Partners upgraded the previous rating for Grindrod Shipping Holdings Ltd (NASDAQ:GRIN) from Neutral to Buy. For the first quarter, Grindrod Shipping Hldgs had an EPS of $0.22, compared to year-ago quarter EPS of $1.56. At the moment, the stock has a 52-week-high of $26.29 and a 52-week-low of $6.80. Grindrod Shipping Hldgs closed at $8.57 at the end of the last trading period. JP Morgan upg